<DOC>
	<DOCNO>NCT03002389</DOCNO>
	<brief_summary>Hyper polarize xenon-129 MRI ( HXe MRI ) unique image test detect air flow lung oxygen move inhale air blood . Chronic Obstructive Pulmonary Disease ( COPD ) disease patient develop narrowing airway , thus , difficulty breathe air lung also damage lung tissue patient need move oxygen air blood . In study , two drug already approve FDA ( Anoro Arnuity ) administer patient already know COPD . While patient treat two drug ( one drug time month ) , lung health use usual test method ( CT scan lung , pulmonary function test , blood test ) assess addition HXe MRI . The goal study prove HXe MRI excellent image test show state lung health among COPD patient also obtain new information lung health change drug already approve US FDA . This work anticipate help develop HXe MRI new clinical test guide treat patient COPD new therapy improve lung health patient COPD .</brief_summary>
	<brief_title>Hyperpolarized Xenon-129 MRI : New Multi-dimensional Biomarker Determine Pulmonary Physiologic Responses COPD Therapeutics</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Xenon</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>post bronchodilator PFT spirometry FEV1/FVC &lt; 70 % predict History diagnosis COPD History alpha 1 antitrypsin deficiency previous diagnosis asthma , interstitial lung disease , pulmonary vascular disease , inability complete MRI assessment testing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>emphysema</keyword>
	<keyword>MRI</keyword>
	<keyword>hyper polarize gas MRI</keyword>
</DOC>